We tested serial serum samples for hepatitis C virus RNA from patients undergoing treatment for chronic hepatitis C with interferon-a using an assay that combined reverse transcription and polymerase chain reaction. The subjects studied were 20 patients with chronic hepatitis who had serum antibody
HCV RNA in patients with chronic hepatitis C treated with interferon-α
✍ Scribed by T. Jake Liang; Vinod Rustgi; Eithan Galun; Hubert E. Blum
- Publisher
- John Wiley and Sons
- Year
- 1993
- Tongue
- English
- Weight
- 954 KB
- Volume
- 40
- Category
- Article
- ISSN
- 0146-6615
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
In order to assess the efficacy of interferon‐α on hepatitis C viral RNA in patients with chronic hepatitis C, we analyzed the levels of HCV RNA in sera and liver tissues of 16 patients pre‐ and posttreatment using a semiquantitative polymerase chain reaction method. Fifteen of 16 patients were positive for anti‐HCV antibodies by four‐antigen recombinant immunoblot assay (4‐RIBA). Only two patients demonstrated normalization of ALT in response to interferon; three patients showed a partial response. Only one patient from the partial responder group displayed a significant reduction of HCV RNA level posttreatment. In the nonresponder group, several patients, although their ALTs remained elevated, demonstrated significant decreases in HCV RNA levels in either serum or liver in response to interferon. Our data suggest that interferon treatment of chronic hepatitis C may not be effective in eradicating HCV infection and a reduction in ALT is infrequently associated with a decrease in HCV RNA level in either serum or liver. Cessation of treatment is frequently associated with the recrudescence of HCV replication and disease. © 1993 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
Detection and quantification of hepatitis C virus (HCV) RNA levels by using the standardized qualitative Amplicor™ HCV and quantitative Amplicor HCV Monitor™ assays (Roche Molecular Systems) were evaluated in 48 patients with chronic hepatitis C treated with interferon. Results were compared with an
We quantified serum hepatitis C virus RNA titers and determined hepatltis C virus subtypes in chronic hepatitis C patients treated with interferon$ to investigate relationships among serum ALT response, serum hepatitis C virus titer and hepatitis C virus subtype. Of 146 chronic hepatitis C patients
## Abstract Hepatitis C virus (HCV), a positive stranded RNA virus, is the main causative agent of post‐transfusion and sporadic non‐A non‐B hepatitis worldwide. Paired samples of plasma and peripheral blood mononuclear cells (PBMC) from 11 patients with chronic hepatitis C treated with α‐interfero
We reanalyzed the results of a pilot study of recombinant alpha-interferon therapy for chronic non-A, non-B hepatitis in light of the recent discovery of the hepatitis C virus and the development of diagnostic assays for this agent. Stored serum samples from 10 patients treated between 1984 and 1986
## Abstract In interferon treatment of chronic hepatitis C patients, the biochemical and virological responses mostly parallel each other. However, some patients who show persistent ALT normalization display continued viremia after cessation of therapy. High‐density hepatitis C virus (HCV) particle